Age Related Macular Degeneration Amd Market Report
First published: 11 October 2024 | Last updated: 21 April 2026 | Report Code: age-related-macular-degeneration-amd
Age Related Macular Degeneration Amd Market — USD $8 Billion in 2023, Growing to USD 16.35null by 2033 at 7.2% CAGR
This report provides a comprehensive analysis of the Age Related Macular Degeneration (AMD) market, covering the market size, growth forecasts, industry trends, and regional insights for the period 2023-2033.
Key Takeaways
- Market expands from $8.00 Billion in 2023 to $16.35 Billion by 2033, reflecting a 7.2% CAGR over 2023 to 2033.
- North America is both the largest market and the fastest-growing region, with notable share and growth through the forecast.
- Europe and Asia Pacific show substantial increases: Europe rises from $2.37 Billion to $4.84 Billion; Asia Pacific from $1.47 Billion to $3.00 Billion.
- Top industry participants include Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG and Alcon Inc.
- Distribution and treatment mixes — including pharmaceuticals, surgical procedures and nutritional supplements — remain central to market dynamics.
Age Related Macular Degeneration Amd Market Report — Executive Summary
This report provides a focused examination of the Age Related Macular Degeneration Amd Market Report across the 2023 to 2033 forecast. The market recorded a value of $8.00 Billion in 2023 and is projected to reach $16.35 Billion by 2033 at a 7.2% CAGR. Key growth levers include therapeutic innovation, evolving treatment pathways, and expanding distribution channels. Regional breakdowns show North America leading in both current size and growth rate. The analysis is organized by disease type, treatment type, stage of disease, and distribution channel, with company profiles for major players such as Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG and Alcon Inc. The report highlights trends shaping adoption and competitive positioning while outlining challenges that may affect uptake and access.
Key Growth Drivers
- Continued development of therapeutic options and procedural interventions expanding treatment availability and clinical pathways.
- Broader distribution infrastructure including hospital, retail and online pharmacies improving access to AMD therapies.
- Sustained focus from major industry players on pipeline development and commercialization, supporting market expansion.
- Regulatory frameworks that enable introduction of new treatments and support market entry for innovative solutions.
- Rising attention to disease management and diagnostic practices prompting earlier detection and treatment initiation.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $8.00 Billion |
| CAGR (2023-2033) | 7.2% |
| 2033 Market Size | $16.35 Billion |
| Top Companies | Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG, Alcon Inc. |
| Published Date | 11 October 2024 |
| Last Modified Date | 21 April 2026 |
Age Related Macular Degeneration Amd Market Overview
Customize Age Related Macular Degeneration Amd Market Report market research report
- ✔ Get in-depth analysis of Age Related Macular Degeneration Amd market size, growth, and forecasts.
- ✔ Understand Age Related Macular Degeneration Amd's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Age Related Macular Degeneration Amd
What is the Market Size & CAGR of Age Related Macular Degeneration Amd Market Report market in 2023?
Age Related Macular Degeneration Amd Industry Analysis
Age Related Macular Degeneration Amd Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Age Related Macular Degeneration Amd Market Report Market Analysis Report by Region
Europe Age Related Macular Degeneration Amd Market Report:
Europe is expected to grow from $2.37 Billion in 2023 to $4.84 Billion in 2033. The region’s expansion reflects steady uptake across treatment categories and continued commercialization efforts by major industry players.Asia Pacific Age Related Macular Degeneration Amd Market Report:
Asia Pacific progresses from $1.47 Billion in 2023 to $3.00 Billion in 2033. Growth is driven by increasing treatment adoption and evolving access through diverse distribution channels across the region.North America Age Related Macular Degeneration Amd Market Report:
North America is the largest and fastest-growing region, with market value rising from $2.99 Billion in 2023 to $6.11 Billion in 2033. Regional momentum is supported by strong commercial activity, established distribution channels and active participation from key firms.South America Age Related Macular Degeneration Amd Market Report:
Middle East & Africa Age Related Macular Degeneration Amd Market Report:
Middle East and Africa grows from $0.9 Billion in 2023 to $1.83 Billion in 2033. Growth factors include widening access to therapies and expanding clinical and commercial initiatives in select markets.Tell us your focus area and get a customized research report.
Research Methodology
Age Related Macular Degeneration Amd Market Analysis By Disease Type
The AMD market segmentation by disease type highlights Dry AMD commanding a significant market share with a size of $6.54 billion in 2023, expected to grow to $13.37 billion by 2033, holding steady at 81.78% market share. Wet AMD, while smaller, is projected to grow from $1.46 billion to $2.98 billion, maintaining an 18.22% share.
Age Related Macular Degeneration Amd Market Analysis By Treatment Type
Pharmaceuticals represent the largest share in treatment types, valued at $5.36 billion in 2023, expected to reach $10.95 billion by 2033 with a 66.97% market share. Surgical procedures and nutritional supplements are also crucial, with sizes expected to grow from $1.67 billion to $3.41 billion and $0.98 billion to $2.00 billion, respectively.
Age Related Macular Degeneration Amd Market Analysis By Distribution Channel
The distribution channel segment indicates that Hospital Pharmacies hold a significant market share of $5.36 billion in 2023 and is projected to double to $10.95 billion by 2033. Retail and online pharmacies follow, with estimated values growing considerably within the same period.
Age Related Macular Degeneration Amd Market Analysis By Stage Of Disease
The segmentation by disease stage reveals that the Early Stage holds a substantial market size of $5.36 billion in 2023, anticipated to grow to $10.95 billion. The Intermediate and Advanced Stages are also growing segments, driven by the increasing prevalence of AMD.
Age Related Macular Degeneration Amd Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Age Related Macular Degeneration Amd Industry
Regeneron Pharmaceuticals, Inc.:
A leading player in the AMD market known for its innovative treatments and high-quality research, particularly in developing drug therapies for Wet AMD.Novartis AG:
A global healthcare leader that offers a range of treatments for AMD and is heavily involved in research, focused on improving patient outcomes through innovative therapies.Roche Holdings AG:
Notable for its significant contributions towards advancing AMD treatment solutions, Roche emphasizes precision medicine in its offerings.Bayer AG:
Bayer is recognized for its extensive range of products related to eye diseases, especially for its commitment to research and development in AMD treatments.Alcon Inc.:
A global leader in eye care, Alcon provides a range of surgical and pharmaceutical products targeting AMD, committed to enhancing patient care.We're grateful to work with incredible clients.
FAQs
What is the market size in 2023?
The market size for 2023 is $8.00 Billion as reported for the Age Related Macular Degeneration Amd Market Report.
How big will the market be in 2033?
The market is projected to reach $16.35 Billion in 2033, according to the forecast provided in the report.
What is CAGR for the forecast period?
The compounded annual growth rate for the 2023 to 2033 forecast period is 7.2% as stated in the report data.
Which region is the largest?
North America is identified as the largest region in the market, holding the highest regional value among the areas reported.
Which region is the fastest Growing?
North America is noted as the fastest-growing region in the report, showing the strongest growth trajectory over the forecast span.
Who are the top companies in the market?
Top companies listed in the report include Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG and Alcon Inc.
What are the main treatment types covered?
The report covers Pharmaceuticals, Surgical Procedures and Nutritional Supplements as primary treatment-type categories for AMD management.
How is the market segmented?
Segmentation includes disease type, treatment type, stage of disease and distribution channel, with specific subsegments listed for each category.
Why is the market growing?
Growth is supported by advances in therapeutic options, expanded distribution channels, continued industry investment and evolving clinical management approaches.
What research methods were used?
The study used primary interviews with industry experts, secondary company and publication research, data triangulation and internal validation plus expert-led analysis.